GlobalLux RX Announces Positive Pilot Bioequivalence Results for Oncology Product, Cabozantinib Tablets, Supporting Day 1 Launch in High-Value U.S. and EU Markets
Global Lux RX has generated positive pilot bioequivalence (BE) results for its Cabozantinib Tablets, demonstrating pharmacokinetic alignment with the reference product and supporting a Day 1 launch strategy in both U.S. and EU markets.
Cabozantinib is a widely used targeted therapy for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC), with global sales approaching ~$3 billion annually. The U.S. market alone contributes over $2.1 billion, while Europe and the rest of the world account for an additional ~$700â800 million, highlighting a highly attractive and geographically diversified opportunity. The combined U.S. and EU markets are expected to grow at a 6â8% CAGR over the coming years.
With encouraging pilot BE data indicating alignment with the reference product, Global Lux RXâs Cabozantinib Tablets represent a de-risked development pathway for prescribers and payers. The asset is positioned for rapid uptake, supported by a ~$3 billion market opportunity across the U.S. and EU.
The program is advancing toward pivotal BE readiness, with dossier readiness targeted for Q1 2027 and an EU DCP slot already reserved for Q1 2027, supporting timely market entry. The company is actively seeking out-licensing partners to maximize commercial reach and value creation.
For further discussion or to explore collaboration opportunities, please contact:
Maxim Vlasenko
Business Development & Strategy Lead at GlobalLux Rx
Contact maxim.vlasenko@globalluxrx.comGlobal Lux RX has generated positive pilot bioequivalence (BE) results for its Cabozantinib Tablets, demonstrating pharmacokinetic alignment with the reference product and supporting a Day 1 launch strategy in both U.S. and EU markets.
Cabozantinib is a widely used targeted therapy for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), and differentiated thyroid cancer (DTC), with global sales approaching ~$3 billion annually. The U.S. market alone contributes over $2.1 billion, while Europe and the rest of the world account for an additional ~$700â800 million, highlighting a highly attractive and geographically diversified opportunity. The combined U.S. and EU markets are expected to grow at a 6â8% CAGR over the coming years.
With encouraging pilot BE data indicating alignment with the reference product, Global Lux RXâs Cabozantinib Tablets represent a de-risked development pathway for prescribers and payers. The asset is positioned for rapid uptake, supported by a ~$3 billion market opportunity across the U.S. and EU.
The program is advancing toward pivotal BE readiness, with dossier readiness targeted for Q1 2027 and an EU DCP slot already reserved for Q1 2027, supporting timely market entry. The company is actively seeking out-licensing partners to maximize commercial reach and value creation.
For further discussion or to explore collaboration opportunities, please contact:
Maxim Vlasenko
Business Development & Strategy Lead at GlobalLux Rx
